Patent details

92496 Product Name: Combinaison de dapagliflozine ou d'un sel pharmaceutiquement acceptable de celle-ci et de metformine ou d'un sel pharmaceutiquement acceptable de celle-ci, telle que protégée par le brevet de base EP1506211 B1

Basic Information

Publication number:
92496
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP037366432
Legal Status:
Active
Application number:
92496
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/13/900
Marketing Authorization Type:
Marketing Authorization Date:
16/01/2014
Marketing Authorization Status:
Accepted
Marketing Authorization Country:

Dates

Filing date:
10/07/2014
First Marketing Authorization date:
16/01/2014
Grant date:
10/09/2014
Activation date:
15/05/2023
Publication date:
10/09/2014
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
15/05/2028
SPC Extension Expiration:
15/05/2028
Rejection date:
Withdrawal date:

Owner

From:
10/07/2014
 
 

Name:
ASTRAZENECA AB
Address:
VÄSTRA MÄLAREHAMNEN 9, 151 85, SÖDERTÄLJE, Sweden (SE)

Agent

Name:
MARKS & CLERK LLP
From:
10/07/2014
Address:
BP 1775, 1017, LUXEMBOURG, Luxembourg (LU)
To:

Inventor

1

Name:
SHER Philip, M.
Address:
United States (US)

2

Name:
ELLSWORTH Bruce
Address:
United States (US)

3

Name:
MENG Wei
Address:
United States (US)

4

Name:
WASHBURN William, N.
Address:
United States (US)

5

Name:
WU Gang
Address:
United States (US)

Publication

Bulletin

Bulletin Heading:
SPC3
Bulletin edition number:
2025/04
Publication date:
04/03/2025
Description:
Section E : Supplementary Protection certificates entered into force – IA publication

Annual Fees

Annual Fee Due Date:
01/06/2026
Annual Fee Number:
24
Annual Fee Amount:
440 Euro
Expected Payer:
Last Annual Fee Payment Date:
23/04/2025
Last Annual Fee Paid Number:
23
Last Annual Fee Paid Amount:
430 Euro
Payer:
ANAQUA SERVICES (ANC. SGA2)
Filing date Document type Number of pages
12/08/2022 Request For Change 1
02/09/2022 Outgoing Correspondence 56